Attention Deficit Disorder With Hyperactivity Clinical Trial
Official title:
Treatment of Meta-Cognitive Deficits in Adults With ADHD
This study will determine the effectiveness of group cognitive-behavioral therapy as compared to a problem-solving social support group in treating problems of time management, organization, and planning in adults with attention deficit hyperactivity disorder (ADHD).
ADHD is a chronic neurobiological condition that affects people of all ages, genders, and
races. Symptoms of ADHD may include, but are not limited to, the following: poor attention
span; physical restlessness or hyperactivity; excessive impulsivity; chronic
procrastination; frequently losing things; poor organization, planning, and time management
skills; and excessive forgetfulness. Not every person with ADHD exhibits all of these
symptoms, and the severity of the disorder can range from mild to severe. While there is no
cure for ADHD, the condition can be managed with an accurate diagnosis and proper treatment.
Left untreated, individuals with ADHD may experience significant impairment in social,
emotional, occupational, and academic functioning. Stimulant and non-stimulant medications
are usually effective in alleviating symptoms of ADHD in adults. However, some research
suggests that medications may not effectively treat self-management functioning problems and
that as many as one-third of adults with ADHD have inadequate responses to medication
treatment. Additional research on the benefits of psychosocial treatments for ADHD in adults
is needed. This study will determine the effectiveness of group cognitive-behavioral therapy
as compared to a problem-solving social support group in treating problems of time
management, organization, and planning in adults with ADHD.
Individuals interested in participating in this study will first undergo an assessment of
their eligibility for inclusion in the study. The assessment will last approximately 6
hours, but can be broken up into as many as 4 separate visits. Eligible participants will be
randomly assigned to either receive group cognitive-behavioral therapy or join a
problem-solving social support group. Both groups will meet once a week for 12 weeks. Each
session will last roughly 2 hours and will focus on building time management,
organizational, and planning skills. Time management, planning, and organizational skill
levels will be assessed at the treatment mid-point, immediately following the intervention,
and at 3 and 6 months following the treatment. Self-esteem and symptoms of depression and
anxiety will also be measured at these visits.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00202605 -
Safety and Efficacy of SPD465 in Adults With ADHD
|
Phase 2 | |
Not yet recruiting |
NCT02677519 -
A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD
|
Phase 4 | |
Completed |
NCT02730572 -
Concerta (Methylphenidate) -To-Generic Switch Study
|
N/A | |
Completed |
NCT01681082 -
Psychological Effects of Tai Chi Training
|
N/A | |
Active, not recruiting |
NCT01330693 -
Cortical Excitability: Phenotype and Biomarker in Attention-deficit, Hyperactivity Disorder (ADHD) Therapy
|
Phase 3 | |
Completed |
NCT00830700 -
Children's Attention Deficit Disorder With Hyperactivity (ADHD) Telemental Health Treatment Study
|
N/A | |
Completed |
NCT01012622 -
An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD)
|
Phase 4 | |
Completed |
NCT00626236 -
Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems
|
Phase 2 | |
Completed |
NCT00598182 -
Adherence and Long-term Effect of OROS Methylphenidate (CONCERTA): A Follow-up Study
|
N/A | |
Completed |
NCT00381407 -
Organizational Skills Training for Children With Attention Deficit Hyperactivity Disorder
|
N/A | |
Completed |
NCT00247572 -
Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories
|
Phase 2 | |
Completed |
NCT00178503 -
Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children
|
Phase 2/Phase 3 | |
Completed |
NCT00118911 -
Cognitive Behavioral Therapy for Treatment of Adult Attention Deficit Hyperactivity Disorder
|
N/A | |
Completed |
NCT00557011 -
NRP104, Adderall XR or Placebo in Children Aged 6-12 Years With ADHD
|
Phase 2 | |
Completed |
NCT00218322 -
Effectiveness of ATMX in Treating Adolescents With ADHD and SUD
|
Phase 4 | |
Completed |
NCT00071656 -
Psychosocial Treatment for Attention Deficit Hyperactivity Disorder (ADHD) Type I
|
N/A | |
Active, not recruiting |
NCT00057668 -
Preventing Behavior Problems in Children With ADHD
|
Phase 2 | |
Completed |
NCT00050622 -
Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)
|
N/A | |
Completed |
NCT00050050 -
Cognitive Behavioral Therapy for Adult Attention Deficit Hyperactivity Disorder
|
Phase 1 | |
Completed |
NCT00031395 -
Clonidine in Attention Deficit Hyperactivity Disorder (ADHD) in Children
|
Phase 3 |